What the author is describing is two separate trends. One trend relates to the rapidly dropping cost of genetic studies -- this leads to easier and cheaper ide

What the author is describing is two separate trends. One trend relates to the rapidly dropping cost of genetic studies -- this leads to easier and cheaper identification of human mutations, novel microbial species, comparative genomics, etc. The other trend is for outsourcing of specific biological experiments to what used to be called "contract research organizations" (CROs) and now are "startups". The "silicon valley company" "Mousera" referred to seems to be one of these re-branded CROs. This particular trend has been encouraged by the flight of experienced scientists from the rapidly contracting amount of basic research performed in Big Pharma (check the resumes of those involved). While this combination makes it easier for a "virtual company" to get off the ground, it does not really equate to the sort of startup that the software industry is familiar with -- it might be more similar to hardware startups (though that's not my field, so feel free to correct.) As to costs, the cost of genetics will continue to drop, but the outsourcing of experiments will not render them any cheaper than before (most likely), as the neo-CROs also want to profit.